CelLBxHealth has completed an oversubscribed US$10.9 million fundraise

December 2025 — CelLBxHealth has completed an oversubscribed US$10.9 million fundraise comprising a placing, subscription and retail offer.

CelLBxHealth is a specialist diagnostics company. Its proprietary Parsortix® technology can capture and harvest very rare cells, including circulating tumor cells (CTCs), from a blood sample. Parsortix has received FDA clearance for clinical use to guide precision cancer care.

Our role in the transaction

Oaklins Cavendish, one of Oaklins’ member firms in the UK, advised and supported CelLBxHealth in its fundraise. The transaction was particularly challenging given the company’s previously disclosed funding runway into the first quarter of 2026, as well as the rapid onboarding of a new management team. The new team, led by Jan Groen and Peter Collins, was delighted by the level of support from existing holders alongside substantial interest from new investors. Notably, the company raised more than twice its market capitalization, with investor demand ultimately scaled back. The strength of participation reflects investor support for the company’s strategy, its new leadership and confidence in its core technology.

Service

Funding, debt advisory & ECM

Parties

“We were delighted to see strong support in the fundraise from both existing shareholders and non-holders. This heavily oversubscribed funding gives us the much-needed capital to pursue our revised business strategy as we focus on the substantial market opportunity for the Parsortix platform. It was a pleasure working with Oaklins Cavendish, whose support helped bring all sides of the business together to deliver a successful fundraise despite very challenging circumstances. We look forward to significant commercial progress in 2026 and beyond.”

Peter Collins

Interim CEO, CelLBxHealth

Talk to the deal team

Geoff Nash

Director

London, United Kingdom
Oaklins Cavendish

View profile Get in touch

Related deals

Life & Mobility has attracted investor Bolster Investment Partners

Private Equity | Healthcare

Life & Mobility has attracted investor Bolster Investment Partners

Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.

Learn more

Asana Gruppe has sold selected outpatient service areas to Luzerner Kantonsspital

Healthcare

Asana Gruppe has sold selected outpatient service areas to Luzerner Kantonsspital

Luzerner Kantonsspital (LUKS) has acquired key parts of Asana Spital Menziken AG’s outpatient services from Asana Gruppe AG, including its ambulance service, primary care practice and ambulatory care center. The transaction supports the long-term continuity of local medical care in the Swiss Wynen and Seetal regions and ensures these services remain available close to patients’ homes.

Learn more

Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners and co-investors

Private Equity | Healthcare

Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners and co-investors

Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners alongside co-investors Ouest Croissance, Sodero and CE IDF, with Bpifrance, Océans Participations and the management team reinvesting.

Learn more